Blood Reviews
Volume 21, Issue 5 , Pages 233-243 , September 2007

Therapy of Relapsed Hodgkin Lymphoma

  • Amanda F. Cashen

      Affiliations

    • 660 S. Euclid Ave., Box 8007, St. Louis, MO 63110, Tel.: +1 314 454 8306; fax: +1 314 454 7551.
    • ,
  • Nancy L. Bartlett

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 314 362 5654; fax: +1 314 747 5123.
    • 660 S. Euclid Ave., Box 8056, St. Louis, MO 63110.

References 

  1. Canellos G, Anderson J, Propert K, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484
  2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. The Lancet. 2002;359:2065–2071
  3. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23:6508
  4. Josting A, Franklin J, May M, et al. New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin’s Lymphoma Registered in the Database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2002;20:221–230
  5. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer. 1996;78:1293–1299
  6. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP- ABVD. J Clin Oncol. 1997;15:528–534
  7. Paltiel O, Rubinstein C, Or R, et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplantation. 2003;31:565–569
  8. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplantation. 2003;32:279–285
  9. Sureda A, Arranz R, Iriondo A, et al. Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–1404
  10. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–633
  11. Hasenclever D, Diehl V, Armitage JO, et al. A Prognostic Score for Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514
  12. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002;13:1370–1377
  13. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. British Journal of Haematology. 2001;113:161–171
  14. Jabbour E, Hosing C, Pro B, et al. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin lymphoma (HL). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23(Suppl. 16):6509
  15. Pfreundschuh M, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol. 1994;12:580–586
  16. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13:1628–1635
  17. Alvarez I, Sureda A, Arranz R, et al. Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin’s Lymphoma Patients. ASH Annual Meeting Abstracts. 2005;106:2676
  18. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10:593–595
  19. Venkatesh H, Di Bella N, Flynn T, Vellek M, Boehm K, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clinical Lymphoma. 2004;5:110–115
  20. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol. 1994;5:817–820
  21. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Michael Crump. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106:353–360
  22. Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Zelenetz A, Canellos G. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin’s disease: Preliminary results of CALGB 59804. Proc Am Soc Clin Oncol. 2003;22:#2275
  23. Josting A, Nogova L, Franklin J, et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23:1522–1529
  24. Macdonald DA, Gospodarowicz MK, Wells WA, et al. Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL). Blood. 2005;106:#817
  25. Chopra R, McMillan A, Linch D, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight- year study of 155 patients. Blood. 1993;81:1137–1145
  26. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: Long term follow-up in 128 patients. Ann Oncol. 1993;4:767–773
  27. Holland DW, Engelhardt BG, Goodman SA, et al. High dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma. Journal of Clinical Oncology. 2006;24:7552
  28. Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed hodgkin’s disease. The American Journal of Medicine. 1991;91:605–611
  29. Reece D, Connors J, Spinelli J, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/− cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood. 1994;83:1193–1199
  30. Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. The Lancet. 1993;341:1051–1054
  31. Josting A, Franklin J, Sieniawski M, et al. Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease. Blood. 2005;106:#818
  32. Sureda A, Arranz R, Iriondo A, et al. Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–1404
  33. Burns L, Daniels K, McGlave P, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin’s disease: factors predictive of prolonged survival. Bone Marrow Transplantation. 1995;16:13–18
  34. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biology of Blood and Marrow Transplantation. 1997;3:98–106
  35. Rapoport A, Rowe J, Kouides P, et al. One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993;11:2351–2361
  36. Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome. Ann Oncol. 2003;14:745–751
  37. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96:1280–1286
  38. Ferme C, Mounier N, Divine M, et al. Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin’s Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol. 2002;20:467–475
  39. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. British Journal of Haematology. 2004;124:645–652
  40. Metcalfe TL, Gooley TA, Press OW, et al. Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin’s Lymphoma. ASH Annual Meeting Abstracts. 2005;106:2081
  41. Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. Second autologous stem cell transplant for multiply relapsed Hodgkin’s disease. Bone Marrow Transplantation. 2002;29:763–767
  42. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone A. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol. 1997;15:1595–1600
  43. Fung HC, Stiff P, Nademanee A, et al. Final Report on Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin Lymphoma - A Two Institution Study. ASH Annual Meeting Abstracts. 2005;106:2071
  44. Porter DL, Stadtmauer EA, Lazarus HM. ’GVHD’: graft-versus-host disease or graft-versus-Hodgkin’s disease? an old acronym with new meaning. Bone Marrow Transplantation. 2003;31:739–746
  45. Jones R, Piantadosi S, Mann R, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–537
  46. Anderson J, Litzow M, Appelbaum F, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–2350
  47. Akpek G, Ambinder RF, Piantadosi S, et al. Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma. J Clin Oncol. 2001;19:4314–4321
  48. Gajewski J, Phillips G, Sobocinski K, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–578
  49. Peniket AJ, Elvira MCRd, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation. 2003;31:667–678
  50. Milpied N, Fielding A, Pearce R, Ernst P, Goldstone A. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291–1296
  51. Phillips G, Reece D, Barnett M, et al. Allogeneic marrow transplantation for refractory Hodgkin’s disease. J Clin Oncol. 1989;7:1039–1045
  52. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation. 1997;20:859–863
  53. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biology of Blood and Marrow Transplantation. 2000;6:272–279
  54. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104:3797–3803
  55. Anderlini P, Champlin RE. Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Where Do We Stand?. Biology of Blood and Marrow Transplantation. 2006;12:599–602
  56. Robinson SP, Schmitz N, Taghipour G, Sureda A. Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation. ASH Annual Meeting Abstracts. 2004;104:2322
  57. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet. 2005;365:1934–1941
  58. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation. 2005;35:943–951
  59. Burroughs LM, Maris MB, Sandmaier BM, et al. HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). Biology of Blood and Marrow Transplantation. 2004;10(suppl 1):73
  60. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biology of Blood and Marrow Transplantation. 2006;12:172–183
  61. Anderlini P, Acholonu SA, Okoroji G-J, et al. Donor leukocyte infusions in relapsed Hodgkin’s lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplantation. 2004;34:511–514
  62. Carbone P, Spurr C. Management of patients with malignant lymphoma: A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 1968;28:811–822
  63. Sohier WD, Wong RKL, Aisenberg AC. Vinblastine in the treatment of advanced Hodgkin’s disease. Cancer. 1968;22:467–472
  64. Wilson HE, Louis J. The response of Hodgkin’s Disease to treatment with oral vinblastine sulfate. Ann Intern Med. 1967;67:303–308
  65. O’Dwyer P, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide: Current status of an active anticancer drug. NEJM. 1985;312:692
  66. Leonard JP, Rosenblatt JD, Bartlett NL, et al. Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease. ASH Annual Meeting Abstracts. 2004;104:2635
  67. Ansell SM, Byrd JC, Horwitz SM, et al. Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma. ASH Annual Meeting Abstracts. 2004;104:2636
  68. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity 10.1182/blood-2003-01-0039. Blood. 2003;102:1458–1465
  69. Schnell R, Dietlein M, Staak JO, et al. Treatment of Refractory Hodgkin’s Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody. J Clin Oncol. 2005;23:4669–4678
  70. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98:310–314
  71. Younes A, Fayad L, Pro B, et al. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. ASH Annual Meeting Abstracts. 2005;106:1498
  72. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma 10.1200/JCO.2005.09.018. J Clin Oncol. 2005;23:4390–4398
  73. Goy A, Fayad L, Romaguera J, et al. Preliminary report of a phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin’s disease. European Journal of Haematology. 2004;73:54
  74. Zheng B, Georgakis GV, Li Y, et al. Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors. Clin Cancer Res. 2004;10:3207–3215
  75. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006;107:1731a–1732a
  76. Blum KA, Johnson JL, Niedzwiecki D, Cannellos GP, Cheson BD, Bartlett NL. A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. Journal of Clinical Oncology. 2006;24:#7576
  77. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–623
  78. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease. Blood. 1999;93:3632–3636
  79. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762–1767
  80. Thomson KJ, Peggs KS, Smith P, et al. Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation. ASH Annual Meeting Abstracts. 2005;106:657

PII: S0268-960X(07)00033-1

doi: 10.1016/j.blre.2007.06.001

Blood Reviews
Volume 21, Issue 5 , Pages 233-243 , September 2007

Article Tools

* Image Usage & Resolution